Padagis Us Drug Patent Portfolio
Padagis Us owns 5 orange book drugs protected by 10 US patents with Butoconazole Nitrate having the least patent protection, holding only 1 patent. And Evamist with maximum patent protection, holding 4 patents. Given below is the list of Padagis Us's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9789057 | Pharmaceutical delivery system | 02 Dec, 2026 | Active |
| US6899890 | Bioadhesive drug delivery system | 27 Apr, 2023 | Expired |
| US6978945 | Dispensing device | 30 Nov, 2021 | Expired |
| US6013657 | Pharmaceutical compositions containing mupirocin | 08 Jul, 2018 | Expired |
| US5993856 | Pharmaceutical preparations and methods for their administration | 17 Nov, 2017 | Expired |
| US6299900 | Dermal penetration enhancers and drug delivery systems involving same | 19 Feb, 2017 | Expired |
| US6818226 | Dermal penetration enhancers and drug delivery systems involving same | 19 Feb, 2017 | Expired |
| US6923983 | Transdermal delivery of hormones | 19 Feb, 2017 | Expired |
| US5643602 | Oral composition for the treatment of inflammatory bowel disease | 01 Jan, 2015 | Expired |
| US5643602 | Oral composition for the treatment of inflammatory bowel disease | 01 Jul, 2014 | Expired |
Latest Legal Activities on Padagis Us's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Padagis Us.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 07 Apr, 2021 | US9789057 |
| Notice of Final Determination -Election Required | 09 Jan, 2019 | US6818226 |
|
FDA Final Eligibility Letter
Critical
| 19 Mar, 2018 | US6818226 |
|
Interim Patent Term Extension Granted
Critical
| 31 Jan, 2018 | US6818226 |
|
Recordation of Patent Grant Mailed
Critical
| 17 Oct, 2017 | US9789057 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 17 Oct, 2017 | US9789057 |
|
Issue Notification Mailed
Critical
| 27 Sep, 2017 | US9789057 |
| Dispatch to FDC | 13 Sep, 2017 | US9789057 |
|
Application Is Considered Ready for Issue
Critical
| 12 Sep, 2017 | US9789057 |
|
Issue Fee Payment Verified
Critical
| 11 Sep, 2017 | US9789057 |
|
Issue Fee Payment Received
Critical
| 11 Sep, 2017 | US9789057 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 06 Sep, 2017 | US9789057 |
|
Expire Patent
Critical
| 28 Aug, 2017 | US6923983 |
| transaction for FDA Determination of Regulatory Review Period | 21 Aug, 2017 | US6818226 |
|
Mail Notice of Allowance
Critical
| 12 Jun, 2017 | US9789057 |
Padagis Us's Drug Patent Litigations
Padagis Us's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Sep 04, 2014, against patent number US9789057. The petitioner , challenged the validity of this patent, with Thomas C. Riley et al as the respondent. Click below to track the latest information on how companies are challenging Padagis Us's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9789057 | September, 2014 |
Decision
(23 Mar, 2017)
| Thomas C. Riley et al | |
Padagis Us's Family Patents
Padagis Us Drug List
Given below is the complete list of Padagis Us's drugs and the patents protecting them.
1. Butoconazole Nitrate
Butoconazole Nitrate is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5993856 | Pharmaceutical preparations and methods for their administration |
17 Nov, 2017
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Butoconazole Nitrate's drug page
2. Centany
Centany is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6013657 | Pharmaceutical compositions containing mupirocin |
08 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Centany's drug page
3. Clindesse
Clindesse is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9789057 | Pharmaceutical delivery system |
02 Dec, 2026
(2 years from now)
| Active |
| US6899890 | Bioadhesive drug delivery system |
27 Apr, 2023
(1 year, 6 months ago)
| Expired |
| US5993856 | Pharmaceutical preparations and methods for their administration |
17 Nov, 2017
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clindesse's drug page
4. Entocort Ec
Entocort Ec is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5643602
(Pediatric)
| Oral composition for the treatment of inflammatory bowel disease |
01 Jan, 2015
(9 years ago)
| Expired |
| US5643602 | Oral composition for the treatment of inflammatory bowel disease |
01 Jul, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Entocort Ec's drug page
5. Evamist
Evamist is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6978945 | Dispensing device |
30 Nov, 2021
(2 years ago)
| Expired |
| US6299900 | Dermal penetration enhancers and drug delivery systems involving same |
19 Feb, 2017
(7 years ago)
| Expired |
| US6818226 | Dermal penetration enhancers and drug delivery systems involving same |
19 Feb, 2017
(7 years ago)
| Expired |
| US6923983 | Transdermal delivery of hormones |
19 Feb, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Evamist's drug page